secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-095775
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics Q2 net loss $22.2M; cash runway into Q1 2025; positive CAN-2409 pancreatic data
--------------------------------------------------------------------------------

- Net loss of $22.2M in Q2 2024 vs $9.6M in Q2 2023; includes $13.7M non-cash warrant liability adjustment.
- Cash and cash equivalents $21.5M at June 30, 2024; expects funding operations into Q1 2025.
- CAN-2409 in pancreatic cancer: median OS 28.8 months vs 12.5 months control; 24-month survival 71.4% vs 16.7%.
- CAN-2409 in NSCLC: median OS 20.6 months in ICI-resistant patients; data presented at ASCO.
- Orphan drug designation from FDA for CAN-2409 (pancreatic) and CAN-3110 (rHGG); phase 3 prostate data expected Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024095775/0000950170-24-095775-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024095775/cadl-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095775

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer